Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage by Kuhn, Alexandre et al.
Mutant huntingtin’s effects on striatal gene
expression in mice recapitulate changes observed
in human Huntington’s disease brain and do not
differ with mutant huntingtin length or wild-type
huntingtin dosage
Alexandre Kuhn1,2, Darlene R. Goldstein1, Angela Hodges3,4, Andrew D. Strand5,
Thierry Sengstag2, Charles Kooperberg5, Kristina Becanovic6, Mahmoud A. Pouladi6,
Kirupa Sathasivam7, Jang-Ho J. Cha8, Anthony J. Hannan9, Michael R. Hayden6,
Blair R. Leavitt6, Stephen B. Dunnett3, Robert J. Ferrante10, Roger Albin11, Peggy Shelbourne12,
Mauro Delorenzi2, Sarah J. Augood8, Richard L.M. Faull13, James M. Olson5, Gillian P. Bates7,
Lesley Jones3 and Ruth Luthi-Carter1,*
1Ecole Polytechnique Fe´de´rale de Lausanne (EPFL), 1015 Lausanne, Switzerland, 2National Center of Competence
in Research (NCCR) Molecular Oncology, Swiss Institute of Experimental Cancer Research (ISREC) and Swiss
Institute of Bioinformatics (SIB) 1066 Epalinges, Switzerland, 3Departments of Psychological Medicine and Medical
Genetics, Wales College of Medicine and School of Biosciences, Cardiff University, Heath Park, Cardiff CF14 4XN,
Wales, UK, 4Department of Psychological Medicine, Institute of Psychiatry, King’s College London, London SE5 8AF,
UK, 5Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA, 6Department of Medical Genetics, University
of British Columbia, and Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute,
Vancouver, BC, V5Z 4H4, Canada, 7Department of Medical and Molecular Genetics, King’s College London School of
Medicine, London SE1 9RT, UK, 8MassGeneral Institute of Neurodegenerative Disease (MIND), Massachusetts
General Hospital, Charlestown, MA 02129, USA, 9University Laboratory of Physiology, Oxford OX1 3PT, UK and
Howard Florey Institute, National Neuroscience Facility, University of Melbourne, VIC 3010, Australia, 10Bedford
Veterans Affairs Medical Center and Departments of Neurology, Pathology, Psychiatry, Boston University School of
Medicine, Bedford, MA 07130, USA, 11Geriatrics Research, Education, and Clinical Center, Ann Arbor Veterans Affairs
Medical Center and Department of Neurology, University of Michigan, USA, 12Division of Molecular Genetics, Faculty of
Biomedical and Life Sciences, University of Glasgow, Glasgow G11 6NU, Scotland, UK and 13Department of Anatomy
with Radiology, University of Auckland, Private Bag 92019, Auckland, New Zealand
Received April 17, 2007; Revised and Accepted May 10, 2007
To test the hypotheses that mutant huntingtin protein length and wild-type huntingtin dosage have important
effects on disease-related transcriptional dysfunction, we compared the changes in mRNA in seven genetic
mouse models of Huntington’s disease (HD) and postmortem human HD caudate. Transgenic models expres-
sing short N-terminal fragments of mutant huntingtin (R6/1 and R6/2 mice) exhibited the most rapid effects on
gene expression, consistent with previous studies. Although changes in the brains of knock-in and full-
length transgenic models of HD took longer to appear, 15- and 22-month CHL2Q150/Q150, 18-month HdhQ92/Q92
and 2-year-old YAC128 animals also exhibited significant HD-like mRNA signatures. Whereas it was expected
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that the expression of full-length huntingtin transprotein might result in unique gene expression changes
compared with those caused by the expression of an N-terminal huntingtin fragment, no discernable differ-
ences between full-length and fragment models were detected. In addition, very high correlations between
the signatures of mice expressing normal levels of wild-type huntingtin and mice in which the wild-type
protein is absent suggest a limited effect of the wild-type protein to change basal gene expression or to influ-
ence the qualitative disease-related effect of mutant huntingtin. The combined analysis of mouse and human
HD transcriptomes provides important temporal and mechanistic insights into the process by which mutant
huntingtin kills striatal neurons. In addition, the discovery that several available lines of HD mice faithfully
recapitulate the gene expression signature of the human disorder provides a novel aspect of validation
with respect to their use in preclinical therapeutic trials.
INTRODUCTION
Huntington’s disease (HD) results from a trinucleotide repeat
expansion mutation in exon 1 of the huntingtin (HD, IT15)
gene. The neurotoxicity of this mutation is conveyed
through the expansion of polyglutamine stretch in the corre-
sponding protein product, huntingtin (htt), which appears to
disrupt multiple cellular processes. Among these is the appar-
ent dysregulation of gene expression, which has recently been
implicated through transcriptomic profiling and biochemical
data on huntingtin protein interactions (1). Interest in this
disease mechanism has gained additional momentum by
virtue of preclinical trials showing that transcriptionally
active drugs ameliorate disease phenotype (2–4).
A substantial number of models of HD are available to
conduct studies aimed at understanding and eventually ameli-
orating the human disease. Differences among these model
systems include the length of htt transprotein, length of poly-
glutamine repeat, origin of the mutated htt in the species, host
organism species and strain and levels of htt expression. One
may search among such models for answers to a particular
etiological question based on how well the model system
recapitulates the corresponding aspect of human disease.
R6 lines of mice were produced Mangiarini et al. (5), and
were the first of the HD mice to be recorded. R6/2 mice
express only the exon 1-encoded portion of the human htt
transprotein with a large polyglutamine tract; they have a
severe and rapidly declining molecular and behavioral pheno-
type, with significant motor and mRNA changes by 6 weeks of
age (6–8). However, these mice show no significant neuronal
loss until later time points, ruling out frank degeneration as the
source of mRNA changes (9,10). R6/1 mice, a sister line to the
R6/2, have a similar phenotype that becomes manifest on a
slower timescale (5,11).
Additional transgenic HD mice expressing short N-terminal
htt fragments [such as N171-82Q (12) and HD94 (13)] also
have rapidly declining phenotypes that include changes in
striatal gene expression (14,15). In contrast, HD mice expres-
sing a longer N-terminal portion of htt with 46 polyglutamine
repeats [HD 46 mice (16)] exhibit no detectable changes in
gene expression up to 1 year, and a sister line with 100
repeats shows only subtle neurotransmitter receptor changes
(16,17).
Mouse models designed to recapitulate more precisely the
genetic lesion in human HD have been produced by inserting
CAG repeats into the endogenous mouse HD homolog(Hdh)
gene [including Hdh480Q (18), Hdh92Q (19), CHL2150Q (20),
Hdh140Q (21)]. Also, transgenic mice have been produced
using yeast artificial chromosomes carrying the human hun-
tingtin gene [YAC72 (22) and YAC128 (23)]. These ‘full-
length’ HD models have a normal or near-normal life span,
but show molecular, cellular and behavioral phenotypes
(19–21,23–26; M. Heng and R. Albin, unpublished data).
To date, few gene expression changes have been described
in murine HD models expressing full-length mutant htt
(17,21,25,27).
In this report, we elaborate global transcriptomic compari-
sons between HD mice of all categories and human HD.
The present study focuses on the gene expression in the stria-
tum, the HD brain region demonstrating both the most dra-
matic neuropathology and the most extensive mRNA changes.
Our data show that substantial components of the molecular
HD phenotype can be captured in model systems, and that
these profiles can provide a clear transcriptome level pattern
of disease evolution. Surprisingly, both N-terminal and full-
length mutant htt proteins demonstrate similar effects on
transcription, whereas no detectable effect could be attributed
to wild-type htt. Establishing the significant recapitulation
of the transcriptomic HD phenotype by model systems also
provides an important basis for further investigations of gene-
expression-related HD mechanisms and therapeutics.
RESULTS
Striatal mRNA profiles of seven lines of HD mice expressing
various forms of mutant htt (Table 1) and various gene
dosages of wild-type htt were compared with each other and
with a human HD caudate data set (28). Most of the mice
were sampled de novo for these analyses, but cross-
comparisons to previous data sets (where n  3 arrays were
used) were also included. Each HD mouse model was ana-
lyzed for differential gene expression compared with age-,
gender- and strain-matched wild-type counterparts (see
Materials and Methods). Table 1 provides the details of the
mouse strains, arrays and sample numbers employed for
each data set.
To compare the relative signal magnitudes in each HD
mouse data set, we examined the distributions of nominal
P-values from probe set-wise differential expression tests.
Data sets showing a significant signal are expected to have a
higher proportion of low P-values, whereas the P-values in
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Table 1. HD model data sets and analyses
Model and data set descriptions Single-gene testing Comparison with human HD
Model name Ref. Age Straina mHttb wHttc Qd n mut n wt Array Stagee Raw P, 0.001
(dec./inc.)
FDR P , 0.05
(dec./inc.)
Concordance
coefficient (c)
c rank P-value
rand. labels
P-value
rand. genes
R6/2 (5) 6 w B6/CBA N.h 2 150 7f 7f 430A Early 535 (370/165) 676 (484/192) þ0.160 7 0.0735 0.006
R6/2 (set 1) (5) 12 w B6/CBA N.h 2 209 4 5 430 2.0 Late 2300 (1228/1072) 4219 (1953/2266) þ0.405 3 0.0022 0.000
R6/2 (set 2) (5) 12 w B6/CBA N.h 2 209 5 4 430 2.0 Late 2432 (1178/1254) 4683 (2056/2627) þ0.490 1 0.0001 0.000
R6/1 (5) 24 w CBA N.h 2 113 3 3 U74Av2 Early 37 (37/0) 0 (0/0) þ0.350 4 0.0065 0.000
CHL2(HdhQ150) (20) 15 m B6 2F.m 0 150 3 3 U74Av2 Early 5 (4/1) 0 (0/0) þ0.265 5 0.0053 0.000
CHL2(HdhQ150) (20) 22 m B6/CBA 2F.m 0 155 4 4 430 2.0 Late 2448 (1460/988) 3953 (2125/1828) þ0.440 2 0.0022 0.000
HdhQ92 (19) 3 m B6 2F.mg 0 92 3 3 430 2.0 10 (4/6) 1 (0/1) 20.015 10 0.6094 0.739
HdhQ92 (19) 18 m B6 2F.mg 0 92 3 3 430 2.0 Early 211 (122/89) 11 (7/4) þ0.130 8 0.0202 0.003
Hdh480Q (18) 12 m B6 F.m 1 80 3 3 U74Av2 8 (4/4) 0 (0/0) 0.005 9 0.5097 0.807
YAC128 (23) 12 mh FVB F.h 2 128 4 4 430 2.0 24 (20/4) 0 (0/0) 20.140 11 0.9738 0.992
YAC128 (23) 24 mh FVB F.h 2 128 6 4 430 2.0 90 (34/56) 7 (5/2) þ0.190 6 0.004 0.001
HD46i (16) 12 m B6/SJL N.h 2 46 16 6 11K subB 6 (0/6) 0 (0/0) 20.205 12 0.9384 0.999
RNA samples from seven different mouse models of HD were sampled at various time points, representing a range of disease stages (column ‘Model and data set descriptions’). Information
under the column ‘Single-gene testing’ refers to numbers of probe sets meeting two different criteria for statistical significance in the moderated t-test. Concordance coefficient and permutation
strategies to estimate chance probability of overlap are described in the text and Materials and Methods (data here are from N ¼ 200 mouse genes) and are presented under the column ‘Com-
parison with human HD’. Faithful recapitulation of human disease by the model data set is demonstrated by c. 0 and P, 0.05. P-value estimates were obtained from 10 000 permutations
(rand. labels) or 1000 permutations (rand. genes).
aPredominant mouse background strain(s): B6 ¼ C57Bl/6J, FVB ¼ FVB/N.
bmHtt, mutant htt-encoding genes: number of copies (one or two), protein coding length (N, N-terminal htt fragment; F, full-length htt), species (h, human; m, mouse).
cwHtt, number of copies (zero, one or two) of wild-type htt-encoding mouse Hdh genes.
dQ, mean polyglutamine-encoding CAG repeat expansion size for mutant allele (standard deviation of three to seven repeats).
eDisease stage assigned for meta-analysis (see text and Table 2).
fSaline-injected controls from two independent drug studies were combined for this analysis (see Materials and Methods).
gHuman HD exon 1 replaces exon 1 of mouse Hdh in HdhQ92/Q92.
h12-month and 24-month YAC128 data from (K. Becanovic, M. Pouladi, A. Kuhn, R. Luthi-Carter, M. Hayden and B. Leavitt, unpublished data).
iHD46 data from Chan et al. (17). All other data, this study.
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the absence of such a signal should be distributed randomly,
giving a flat histogram. As shown in Figure 1, such a distinct
peak of small P-values was observed in the 6- and 12-week
R6/2, 22-month CHL2Q150/Q150 and 18-month HdhQ92/Q92
data sets. To summarize the strength of the differential gene
expression signature, we calculated the number of probe sets
meeting the defined statistical criteria in each model (nominal
P-value is ,0.001 or false discovery rate (FDR)-corrected
P-value is ,0.05, Table 1 in columns headed ‘Single-gene
testing’). The number of probe sets meeting these criteria was
considerably higher for some data sets than that of others,
indicating different levels of detectable differential expression.
Nonetheless, several models have changes in gene expression
that can be identified on a single gene-testing basis.
To determine the extent to which the various HD models
recapitulate the transcriptomic changes in human HD
caudate, we compared the mouse HD profiles with microarray
data from human samples of pathological Grade 2 or below
(28) (complementary analysis is given in Supplementary
Material, Table S1). Quantifying the similarity of each
model’s overlap to the human data should thus provide a rela-
tive measure of its ability to reproduce the signature of HD.
The determination of concordant gene expression between
human HD and its mouse models considered whether the stat-
istically top-ranked mRNAs in each mouse data set were con-
sistent with the differential mRNA expression observed in
human HD caudate. First, the top 200 differentially expressed
genes in each model were determined (including both
increases and decreases) and each mouse gene was mapped
to its corresponding human ortholog. Then, the direction of
each change in expression was taken into account, and same-
direction changes were distinguished from changes with oppo-
site signs (Fig. 2). As a third step, a statistical cutoff for the
human comparison was implemented in order to restrict the
overlap to changes identified as statistically significant in
human. Thus, a concordant change was defined as one
showing the same-signed change in expression (increased or
decreased in both mouse and human) meeting a false discov-
ery rate cutoff of P , 0.05 in the human analysis. For each
data set, we then summarized its interaction with human HD
data set using a concordance coefficient (c), which tallied con-
cordant minus discordant regulations (as described in
Materials and Methods; data presented in Table 1 in ‘Concor-
dance coefficient’ column). To estimate the significance of the
relationships between the model and human data sets, we com-
pared the actual concordance coefficients with coefficients
obtained from analyses where the human sample labels were
randomly assigned (Table 1 in ‘P-value rand. labels’
column). Alternatively, we compared the actual concordance
coefficients with coefficients calculated from randomized
selections of mouse probe sets mapped to the human differen-
tial expression list (Table 1 in ‘P-value rand. genes’ column).
The qualitative assessment of which models showed bona
fide HD signal was similarly assigned using both of these
approaches (Table 1). Mouse data sets showing the highest
concordance with human HD were those from 12-week R6/2
and 22-month CHL2Q150/Q150 animals, but concordance with the
data from 24-week R6/1 animals, and 18-month HdhQ92/Q92
animals were also significant (P , 0.05). Interestingly, these
analyses also indicated that two of the data sets that showed no
clear signs of gene expression changes on a single-gene testing
basis, those from the 15-month CHL2Q150/Q150 mice and
24-month YAC128 mice, also had significant overlap with
the gene expression signature of the human HD caudate
(Table 1, Fig. 2). Providing a relative measure of similarity
to human HD, the concordance coefficients and corresponding
ranks of all model data sets are presented in Table 1. To visu-
alize the correlation of fold-change and to consider the specific
direction of change (increased versus decreased), complemen-
tary scatter plots illustrating these features of the data are pre-
sented in Figure 3. For mouse models with a significant
similarity to human HD, there was generally higher concor-
dance between mouse and human data where expression of
particular mRNAs was decreased.
Mouse models showing robust HD signal comprised both
N-terminal fragment and full-length models. To address par-
ticular aspects of HD pathogenesis that might be differentially
represented across models and time points, we compared the
collected data sets with one another. On the basis of different
protein contexts of the mutant polyglutamine stretch in the
knock-in and N-terminal fragment models, we hypothesized
that the two classes of models might show different patterns
of gene expression changes. One could postulate, for
example, that animals expressing full-length mutant htt
might display changes related to both mutant full-length and
N-terminal fragment effects and so an additional set of gene
expression changes would be evident in these animals. We
thus attempted to identify specific gene expression changes
that would distinguish between the two types of models, and
thereby delineate unique effects of full-length mutant htt.
As preliminary results indicated that array type might have
a significant effect on data set discrimination, we increased the
homogeneity of comparisons by restricting analyses to data
sets collected on arrays with identical probes (MOE 430).
Cluster analysis using top knock-in, truncated, transgenic or
human HD gene expression changes or most variable genes
across all HD mouse models typically discriminated between
data sets with significant HD signal and those without, but pro-
vided no discrimination between N-terminal and full-length
HD models (Fig. 4). On the other hand, the emergent pattern
was that models sampled during later stages of disease
(22-month CHL2Q150/Q150 and 12-week R6/2) consistently
clustered together. The strong similarity of late stage models
is also demonstrated by their correlation coefficients of differ-
ential expression (fold-change, Fig. 4, bottom panels), where
data from late stage models are more highly correlated with
each other than with models of the same respective type
(N-terminal or full-length).
When considered together, the numbers and directions of
mRNA changes across mouse model and human HD data
sets showed interesting relationships (Table 1). Overall, the
earliest stage models exhibited fewer changes, and these
were predominantly decreases in expression. As the model
phenotype became more severe (as over time with R6/2 or
CHL2Q150/Q150), the total number of expression changes
increased, and the ratio of increased to decreased changes
became approximately 1:1. As considered in the previous
section, the pattern of molecular changes in the late stage
mice is closest to that seen in human postmortem HD tissue.
Therefore, it is exiting to consider that the potential continuum
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Figure 1. Nominal P-value distributions for differential expression. Model and data set descriptions and differential expression summaries are provided in
Table 1.
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Figure 2. Distribution of top 200 mouse expression changes in the human data set. For each set of differential expression measures (HD mouse versus wild-type
or human HD versus control), genes were ranked by absolute moderated t (see Materials and Methods). Orthologs of the top-ranking mouse genes were then
identified in the human data set and displayed in the histogram according to human rank. Same sign regulations (increased or decreased in both mouse and human
HD) are shown in green; opposite sign regulations (increased in mouse and decreased in human, or vice versa) are shown in red. Frequency represents the frac-
tion of the top 200 mouse expression changes that map to a particular bin of ranks in the human data set (1000 probe sets in each bin). A higher frequency of
concordant (green) than discordant (red) mouse–human ortholog pairs falling within the top 13 862 human ranks (corresponding to FDR P , 0.05) indicates
similarity between model and human HD signatures. The assessment of these patterns for significant relationships between mouse and human data sets is rep-
resented by the concordance coefficient and corresponding P-value estimations (Table 1).
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Figure 3. Scatter plots of differential expression in model versus human HD. These plots provide additional detail about the concordant and discordant changes
shown in Figure 2 and pictorially represent the bases of the concordance coefficients for each model (data in Table 1; procedural descriptions in Results and
Materials and Methods). Numbers summarizing same sign regulations are shown in green (increased in both mouse and human HD, top right quadrants;
decreased in both mouse and human HD, bottom left quadrants); numbers summarizing opposite sign regulations are shown in red (increased in mouse and
decreased in human, bottom right quadrants; decreased in mouse and increased in human, top left quadrants). Grey cirles indicate human orthologs where
FDR P  0.05 in human HD (i.e. orthologs where differential expression in human is considered non-significant) and are not scored as either concordant or
discordant.
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Figure 4. Correlation of M (log2 fold change) of HD effect across mouse models and discrimination of HD model subsets. Top left panels: Heat maps depict
correlation coefficients of M for all pairwise comparisons between models. Genes selected by rank in the data set indicated [(A) 22-month CHL2Q150/Q150;
(B) 12-week R6/2]. Top right panels: hierarchial clustering of models based on differential expression of gene sets indicated. Bottom panels: Scatter plots of
M are shown (for all pairs of models) for gene sets indicated, with correlation coefficients. For all panels, selection of variable numbers of top-ranking
genes (100–1000) achieved similar results. Qualitatively similar results were also obtained using top-ranked genes from human other model data sets, as
well as with a selection of the most variable genes across all models.
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Figure 4. Continued.
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of mRNA pathology may accurately be represented by the
mice as well, with the early stage mice providing information
not readily observable in human HD brain, due to the limited
availability of human tissues representing the very earliest
pathological events.
To explore whether there might be identifiable biological
explanations for the differences between the late stage and
early stage mice, we subjected differential expression lists to
cellular and molecular pathways analyses. To focus on
changes relevant to human HD, we considered only concor-
dant changes in mice whose orthologs were significantly dys-
regulated in human. Unfortunately, however, gene ontology
analyses were unable to detect over- or under-represented
pathways significantly in these gene sets and thus no specific
differences were revealed.
To identify robust molecular indicators that might provide
important information about early disease mechanisms, we
defined the most consistent gene expression changes across
multiple early-stage HD mice (6-week R6/2, 24-week R6/1,
18-month HdhQ92/Q92 and 15-month CHL2 Q150/Q150 mice;
Supplementary Material, Table S1) using a mean rank strategy
(see Materials and Methods and Table 2 legend). Supporting
the robustness of the approach, this meta-analysis list
showed a significant concordance with human HD caudate
(c ¼ 0.25; P ¼ 0.023). We further subselected concordant
gene expression changes by eliminating those that could not
be shown to recapitulate changes in low pathological grade
HD brain, and present the top genes identified by this strategy
to define early disease events in Table 2. (Full meta-analysis
of early and late model changes is available in Supplementary
Material, Tables S2 and S3.) The concordant early changes
include both expected (DRD2, ADORA2A, CNR1 and
PENK) and novel mRNAs (RASGRP2, MYT1L and CA12)
relative to previous reports, with a large fraction nonetheless
being involved in striatal signaling (11,14,28). It is anticipated
that the use of these robust disease indicators may help to
focus transcription-related hypotheses of HD pathogenesis.
DISCUSSION
In this report, we compare the full transcriptomic profile of a
human neurological disease with those of genetic murine
models of the same disease produced in different laboratories.
The benefit of this strategy is that it yields an unbiased analy-
sis of the extent to which the mouse model accurately
represents the disease it attempts to recapitulate. One note-
worthy limitation of this method is that potentially import-
ant features of disease beyond mRNA level changes escape
detection. Another limitation to be considered is that our
data represent only a small number of animals from each
line and time point. Nonetheless, valuable conclusions can
be drawn from animals showing significant HD signal, par-
ticularly where concordance between multiple models is
observed.
Although statistical treatment of microarray expression
measures has largely been refined to a point of consensus,
strategies for global comparisons between large expression
data sets are less well established. Although several methods
for testing gene set enrichment have been proposed to define
and quantify similarity between transcriptomic information
(29–31), one often-discounted element is the sign of differen-
tial expression (increased versus decreased). In the context of
many problems, such as the one considered here, it is of high
biological relevance that the change in the expression is con-
cordant between the two systems considered (32); here, the
modeling would not be considered accurate if, for example,
genes underexpressed in human disease were overexpressed
in the mouse. We implemented a simple strategy of assessing
transcriptomic concordance between mouse and human based
on both the rank and sign of the change in each data set. This
measure takes into account the strength of disease signal (i.e.
the number of accurately reproduced changes) as well as pena-
lizing ‘incorrect’ regulations. Our proposed measure has a
clear biological interpretation and is amenable to statistical
testing by appropriate permutation of the data.
The major finding of this study is that several available
genetic mouse models of HD reliably reproduce the transcrip-
tomic changes of the human HD caudate. This is an exciting
discovery because it suggests that the process by which
these changes arise in the models may also be similar, and
therefore the study of these models may translate well to
understand human HD. In addition to being relevant for new
target identification, this finding indicates that the available
models may be valid for testing current therapeutic strategies
directed at the same pathway(s).
The results of the present study can inform the choice of
models to study changes in gene expression and the timeline
in which such changes can be expected in various model
systems. We cannot be certain about the extent to which the
present transcriptomic analyses can be extrapolated to other
models, but previous evidence shows that some lines not
included here, such as N171-82Q and HD94, do exhibit
similar mRNA changes (14,15). Also, a global view of the
present data suggests that all mutant htt-expressing mice
would show relevant mRNA changes if the rodent lifespan
allowed sufficient disease progression.
There are nonetheless some noteworthy differences between
the molecular and cellular aspects of the HD models employed
here and the corresponding characteristics of the adult-onset
human disorder. The first is that all models demonstrating
gene expression changes possess CAG repeat lengths atypical
of human cases, comprising the equivalent of an allele causing
an early-onset juvenile form of HD. In addition, several of the
models used here are known to have much less brain regional
specificity than adult-onset HD, both in terms of histopathol-
ogy and differential gene expression (8,10,25,28, M. Heng
and R. Albin, in preparation, R. Luthi-Carter, A. Hannan and
J.-H.J. Cha, unpublished data). Therefore, one cannot rule
out that the transcriptomic changes occurring in these models
are more representative of rare juvenile-onset disease, where
a more widespread pathology and a different clinical profile
are observed.
The similarity between the transgenic mouse models and
human HD was much stronger for the genes that are down-
regulated with disease (Fig. 3). This finding is consistent with
the identification of a set of polyglutamine dysregulated
genes subject to an inhibitory effect of mutant htt on the tran-
scriptional machinery (see below). On the other hand, the
increases in gene expression observed in models at late
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stages also show a statistically significant relationship to HD,
and therefore should not be discounted. One potential con-
founding effect in the late-stage mice is that the loss of striatal
neurons and relative increase in glial number may account for
some of the apparent changes in expression, and we did not
address this point in the present study. Whether particular
changes in gene expression occur at an mRNA/neuron level
will therefore require additional analyses with complementary
methods such as in situ hybridization histochemistry or neur-
onal microdissection (28,33). Cell loss in early-stage HD mice
is absent or minimal, and thus would not be anticipated to
have an impact on the array results.
We were surprised not to be able to identify differences
between models expressing an N-terminal fragment and
those expressing full-length htt proteins. The fact that both
have similar effects on gene expression suggests that these
effects are caused by the polyglutamine-bearing region of
the protein. On the other hand, the more protracted timeline
of this effect in the full-length models is consistent with
the hypothesis that transcriptional dysregulation is dependent
on the nuclear accumulation of a proteolytically derived
N-terminal huntingtin fragment (34), supporting that the inhi-
bition of this step may be a promising therapeutic strategy.
It is also interesting to consider that the transcriptomic pro-
files of the mice do not show a discernable effect of the
varying copy numbers of genes encoding wild-type htt
(Table 1). For example, the CHL2Q150/Q150 and R6 mice
show similar profiles, despite the fact that the CHL2Q150/
Q150 expresses no wild-type htt at all whereas the R6/2 has
two intact copies of the Hdh gene. Taken at face value, this
would be inconsistent with a loss-of-htt-function hypothesis
(35), although sequestration of wild-type htt through
co-aggregation or some other ‘dominant-negative’ action of
mutant htt remains plausible explanations.
Although signaling and metabolic perturbations remain
plausible mechanisms for transcriptomic changes in HD
(36,37), there is considerable support for the hypothesis that
mutant htt has a more direct effect on gene expression. The
strongest evidence for a link between RNA biogenesis and
HD pathogenesis is the observation of aberrant interactions
between mutant htt and transcriptional regulatory proteins.
These reported interactors include Sp1 (38), CBP (39),
NCoR (40), CtBP (41), CA150 (42) and REST/NRSF (37).
In most cases, these interactions have been shown to
change the factors’ abilities to control gene expression in a
polyglutamine-length-dependent manner. The polyglutamine-
length-dependent inhibition of histone acetylation has also
been observed, and the reversal of histone acetylation defi-
cits by the administration of histone deacetylase inhibitors
improves the abnormal phenotype in yeast, Drosophila, cell
and mouse models of polyglutamine disease (2,3,43,44). In
parallel, hypermethylation of histones has also been observed,
and this can be ameliorated with anthracycline antibiotics in
HD mice (45,46).
While much is known about transcriptomic dysregulation in
HD models, the extent to which this information would be rel-
evant to human disease has not previously been established.
The present findings support that HD mice are indeed a
valid substrate for studying mechanisms underlying gene
expression changes in HD. Further, the reference signature
provided by early-stage HD mice may be informative in
prioritizing the future study of transcription-related mechan-
isms of HD pathogenesis.
MATERIALS AND METHODS
Human and mouse samples and differential gene
expression analysis
Human samples, microarray processing and quality control as
well as statistical analysis were performed essentially as
described in Hodges et al. (28). Statistical analyses were
carried out with open source R software packages available
as part of the Bioconductor project (http://www.bioondutor.
org). After quantification of gene expression by robust multi-
array analysis (47,48) using the affy package (49), differential
gene expression between HD (Grades 0–2) and controls was
determined by computing empirical Bayes moderated
t-statistics with the limma package (50,51), including all
probe sets and correcting gene expression for collection site
(Boston or New Zealand), gender and age (,45, 45–60,
60–70 and .70 years).
For each mouse HD model, we quantified gene expression
as for human samples. The number of mutant and wild-type
samples used for the analysis of each model mouse is indi-
cated in Table 1. Differential gene expression between each
HD model and its respective wild-type controls was deter-
mined by computing empirical Bayes moderated t-statistics
with the limma package (50,51), including all probe sets.
Samples from 6-week-old R6/2 mice were pooled across two
experiments (sample sizes of three and four, respectively)
and we (linearly) corrected gene expression for experimental
group.
Comparison of differential gene expression in
HD models versus HD patients
Orthologous probe sets on mouse and human microarrays
were matched using the Bioconductor package annotation-
Tools and HomoloGene, as of August 2006 (52).
Data from each of the HD mouse models were compared
with the human HD signature as follows: we selected the
top N non-redundant probe sets (i.e. representing N different
genes) showing most significant differential expression
between mutant and wild-type animals (i.e. the N non-
redundant probe sets with highest absolute mod t-statistic)
and having one or more orthologous probe sets in human
data. Note that in the case of multiple orthologous probe
sets (i.e. annotated to a single gene), we retained the ortho-
logous probe set detecting the most significant expression
change and excluded the others. Differential mRNA expression
reported by pairs of (orthologous) probe sets detecting a change
in the same direction in mouse and human (i.e. up- or down-
regulation in both mouse and human) was called concordant;
opposite direction changes detected by a pair of orthologous
probe sets in mouse and human was called discordant (i.e.
upregulation in mouse and downregulation in human, or the
reverse). We identified the ranks of orthologous probe sets in
the list of all human probe sets ordered by decreasing evidence
of differential expression (i.e. increasing P-value or decreasing
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Table 2. Top-ranked early mouse changes concordant with human caudate
R6/1 24w R6/2 6w CHL2 15m Q92 18m Human Gene name Gene symbol U74A ps mouse 430A ps mouse U133 ps human
20.83 20.93 20.94 20.99 20.80 RAS, guanyl releasing protein 2 RASGRP2 103282_at 1417804_at 208206_s_at
20.51 20.83 21.03 20.51 21.47 myelin transcription factor 1-like MYT1L 96496_g_at 1460111_at 210016_at
20.57 20.63 20.40 20.54 21.04 calcium channel, voltage-dependent, alpha2/delta subunit 3 CACNA2D3 98300_at 1419225_at 219714_s_at
20.69 20.87 20.77 20.44 21.08 inositol 1,4,5-triphosphate receptor 1 ITPR1 94977_at 1457189_at 211323_s_at
20.71 20.33 20.37 20.83 21.09 carbonic anyhydrase 12 CA12 103905_at 1428485_at 204508_s_at
20.25 20.54 20.76 20.96 21.07 regulator of G-protein signaling 14 RGS14 102711_at 1419221_a_at 211021_s_at
20.68 20.53 20.32 20.64 21.60 potassium voltage-gated channel, shaker-related subfamily, beta member 1 KCNAB1 102725_at 1448468_a_at 210471_s_at
20.70 21.12 20.78 21.08 21.23 adenosine A2a receptor ADORA2A 101363_at 1427519_at 205013_at
20.56 20.79 20.44 20.49 21.34 hippocalcin HPCA 99944_at 1450930_at 205454_s_at
20.55 20.28 20.31 20.89 21.71 cannabinoid receptor 1 (brain) CNR1 99892_at 1434172_at 213436_at
20.71 21.42 21.08 20.84 21.68 cAMP-regulated phosphoprotein 19 ARPP-19 97259_at 1422609_at 214553_s_at
20.69 20.83 20.40 20.69 20.77 gamma-aminobutyric acid (GABA-A) receptor, subunit delta GABRD 99342_at 1449980_a_at 208457_at
20.50 20.51 20.74 20.93 20.83 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 ST8SIA3 99504_at 1451008_at 208065_at
20.47 20.41 20.24 20.54 21.03 Rap 1 GTPase-activating protein RAP1GAP 160822_at 1428443_a_at 203911_at
20.37 20.48 20.32 20.32 20.33 potassium channel tetramerization domain containing 17 KCTD 17 102099_f_at 1435525_at 205561_at
20.48 20.33 20.46 20.63 20.60 UDP-GlcNAc:beta Gal beta-1,3-N-acetylglucosaminyltransferase 2 B3GNT2 160137_at 1450026_a_at 219326_s_at
20.83 20.79 20.63 20.80 21.68 coagulation factor C homolog (Limulus polyphemus) COCH 103317_at 1423285_at 205229_s_at
20.33 20.23 20.38 20.57 20.29 POU domain, class 3, transcription factor 1 POU3F1 102652_at 1460038_at 210475_at
20.54 20.74 20.55 20.48 20.72 homer homolog 1 (Drosophila) HOMER1 104499_at 1437363_at 226651_at
20.40 20.78 20.35 20.59 20.42 D site albumin promoter binding protein DBP 160841_at 1418174_at 209782_s_at
20.75 20.54 20.31 20.74 21.52 protein tyrosine phosphatase, non-receptor type 5 PTPN5 100406_at 1425131_at 233471_at
20.57 20.42 20.47 20.35 20.79 ATPase, Ca2þ transporting, cardiac muscle, slow twitch 2 ATP2A2 99570_s_at 1443551_at 212361_s_at
20.53 20.72 20.51 20.81 20.56 dopamine receptor 2 DRD2 97776_s_at 1418950_at 206590_x_at
20.45 20.32 20.67 20.36 20.33 zinc finger protein 706 ZNF706 97463_g_at 1426678_at 227132_at
20.37 20.51 20.80 20.90 20.37 retinoid X receptor 2 RXRG 92237_at 1418782_at 205954_at
20.81 21.41 20.24 21.26 21.38 preproenkephalin 1 PENK 94516_f_at 1427038_at 213791_at
20.64 20.61 21.02 20.43 21.11 protein kinase C beta 1 PRKCB1 99510_at 1460419_a_at 228795_at
20.34 20.33 20.40 20.22 20.43 spermidine synthase SRM 92540_f_at 1421260_a_at 201516_at
20.62 21.00 20.26 20.75 20.91 phosphodiesterase 1B, Ca2þ-calmodulin dependent PDE1B 93382_at 1449420_at 206444_at
20.64 20.55 20.61 20.40 20.58 ATPase, Ca2þ transporting, plasma membrane 2 ATP2B2 95324_at 1433888_at 211586_s_at
20.39 20.35 20.32 20.58 21.36 protein phosphatase 3, catalytic subunit, alpha isoform PPP3CA 95092_at 1438478_a_at 202429_s_at
20.38 20.65 20.53 20.54 20.64 microtubule-associated serine/threonine kinase 3 MAST3 104032_at 1435666_at 213045_at
20.47 20.35 20.39 20.51 20.47 sarcolemma-associated protein SLMAP 98553_at 1426457_at 225243_s_at
20.39 20.46 20.25 20.36 20.66 calcium/calmodulin-dependent protein kinase II, beta CAMK2B 100453_at 1448676_at 213276_at
20.35 20.43 20.23 20.25 20.57 deiodinase, iodothyronine, type II DIO2 103438_at 1418938_at 231240_at
20.38 20.23 20.44 20.49 21.00 phospholipase C, beta 1 PLCB1 92465_at 1425781_a_at 213222_at
20.24 20.42 20.37 20.36 21.10 potassium voltage-gated channel, subfamily Q, member 2 KCNQ2 99449_at 1451595_a_at 205737_at
21.17 20.25 21.35 20.81 21.56 regulator of G-protein signaling 4 RGS4 94155_at 1448285_at 204337_at
20.33 20.63 20.49 20.72 20.39 potassium channel, subfamily K, member 2 KCNK2 104652_at 1449158_at 210261_at
20.44 20.81 20.20 20.44 20.75 brain-specific angiogenesis inhibitor 1-associated protein 2 BAIAP2 99337_at 1451027_at 205294_at
20.44 20.49 20.28 20.41 20.22 ubiquitin-specific peptidase 2 USP2 92820_at 1417168_a_at 229337_at
20.29 20.52 20.30 20.29 20.36 coronin, actin-binding protein, 2B CORO2B 97365_at 1434775_at 209789_at
20.33 20.35 20.34 20.40 20.80 mannosidase 1, alpha MANIA1 160580_at 1417111_at 221760_at
20.38 20.15 20.25 20.36 20.28 membrane-bound transcription factor peptidase, site 1 MBTPS1 95754_at 1448240_at 217543_s_at
20.61 20.73 20.55 20.40 20.75 chemokine (C-X3-C motif) ligand 1 CX3CL1 98008_at 1415803_at 823_at
20.16 20.41 20.17 20.49 20.52 rho guanine nucleotide exchange factor (GEF7) ARHGEF7 98434_at 1449066_a_at 242999_at
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Table 2. Continued
R6/1 24w R6/2 6w CHL2 15m Q92 18m Human Gene name Gene symbol U74A ps mouse 430A ps mouse U133 ps human
20.50 20.65 20.37 20.57 20.55 seizure-related gene 6 SEZ6 92757_at 1427674_a_at 243430_at
20.32 20.55 20.33 20.42 20.51 myeloid ecotropic viral integration site-related gene 1 MEIS2 97988_at 1443926_at 207480_s_at
20.26 20.30 20.20 20.28 21.15 protein phosphatase 1, regulatory (inhibitor) subunit 1A PPP1R1A 96114_at 1422605_at 205478_at
20.34 20.55 20.49 20.32 20.62 cytoplasmic FMR1 interacting protein 2 CYFIP2 102009_at 1442167_at 220999_s_at
20.23 20.43 20.13 20.42 20.50 Harvey rat sarcoma virus oncogene 1 HRAS 160536_at 1424132_at 212983_at
20.34 20.50 20.34 20.39 20.80 guanine nucleotide-binding protein, beta 5 GNB5 100122_at 1422208_a_at 207124_s_at
20.18 20.24 20.13 20.26 20.30 selenophosphate synthetase 1 SEPHS1 94793_at 1455511_at 208940_at
20.25 20.39 20.19 20.27 20.70 adaptor protein complex AP-1, sigma 1 AP1S1 160552_at 1416087_at 205196_s_at
20.21 20.34 20.46 20.33 20.92 guanine nucleotide-binding protein, alpha GNAO1 161902_f_at 1448031_at 204762_s_at
20.30 20.17 20.17 20.29 20.36 cDNA sequence BC008155 C16orf24 94933_at 1425323_a_at 219709_x_at
20.38 20.69 20.26 20.70 21.13 retinal-binding protein 4, plasma RBP4 96047_at 1426225_at 219140_s_at
20.41 20.91 20.24 20.38 21.28 neuronal guanine nucleotide exchange factor NGEF 93178_at 1448978_at 227240_at
20.69 20.55 20.72 20.35 20.44 calcium/calmodulin-dependent protein kinase II alpha CAMK2A 93659_at 1443876_at 213108_at
20.20 20.23 20.27 20.19 20.35 myeloid leukemia factor 2 MLF2 95726_at 1423916_s_at 200948_at
Early stage gene expression changes present in multiple models. All genes meeting the criteria of mean rank 1000 for mouse, rank 5000 in human and concordant sign of change across all
five disease conditions are shown. Number in each column represents log2 fold change of differential expression in each HD group.
H
u
m
a
n
M
o
lecu
la
r
G
en
etics,
2
0
0
7
,
V
o
l.
1
6
,
N
o
.
1
5
1
8
5
7
absolute value of the mod t-statistic) and displayed them in two
separate histograms: one for concordant probe sets and the
other for discordant probe sets. Strong over-representation of
changes in low ranks indicated association between top differ-
entially expressed genes in HD mice and HD patients.
We summarized the association between gene expression
changes in mouse models and human by calculating the con-
cordance coefficient c. The concordant regulation was
defined as a pair of orthologous probe sets reporting same-
direction differential expression between disease and control
(i.e. both upregulated or both downregulated) where the
human probe set showed a significant expression change
(FDR , 0.05) (53). Similarly, discordant regulation was
defined as two probe sets reporting opposite sign regulations
where the human probe set showed a significant expression
change (FDR , 0.05). Let c the concordance coefficient be.
c ¼ # concordant  # discordant
N
where #concordant is the number of concordant orthologous
probe set pairs, #discordant the number of discordant ortholo-
gous probe set pairs and N the number of mouse probe sets
selected for the comparison. c ranges from 21 to 1 and is
interpreted as the normalized difference between the number
of concordant and discordant regulations. c takes a value of
1 if all orthologous probe sets pairs are concordant and a
value of 21 if they are all discordant. A value of 0 either indi-
cates that there are as many discordant as concordant ortholo-
gous probe sets or that no pair is concordant or discordant (i.e.
none of the human orthologs shows significant differential
gene expression).
We tested the strength of association between the mouse
disease signature (i.e. the N selected differentially expressed
mouse genes) and human HD signature, as measured by the
concordance coefficient, in two different ways. First, we
tested whether the association of the model signature with
the human HD signature was significantly stronger than with
an arbitrary (non-HD) human signature. For this purpose, we
generated random human signatures by permuting the original
gene expression measures Yij: for each probe set i in the
human data, we obtained a permuted set of expression
values Yij (with i ¼ 1, . . ., I, I the total number of probe
sets, and j ¼ 1, . . ., J, J the total number of patients) and
obtained an estimate of Mi the log2-fold change between
groups for the permuted values by least squares fitting of the
statistical model as for the original data (see ‘Human and
mouse samples and differential gene expression analysis’).
The permutation was the same for all I probe sets, such that
the correlation between different probe set values was left
unchanged. We repeated the permutation step and obtained
10 000 estimates of Mi. This procedure can be used to esti-
mate the distribution of Mi and test whether mean expression
was equal in HD and control patients [i.e. to assess signifi-
cance of the original Mi (54,55)]. For each permutation, we
thus recalculated the (permuted) concordance coefficient c
based on the log fold change for the N selected mouse regu-
lations and the (permuted) log fold change estimates Mi for
the corresponding N orthologous probe sets. Thus, c provided
an estimate of the association strength of the HD model
signature with a random human signature and the permutation
distribution was used to test for an excess of concordance.
Specifically, we reject the null hypothesis if #{c  c}/
10000 , 0.05, and concluded accordingly that the concor-
dance coefficient observed between the HD model and the
human HD signature was significantly larger than that
between the HD model and an arbitrary human signature
(Table 1, column ‘P-value rand. labels’).
Second, we tested if the association of each model signature
with the human HD signature was significantly stronger than
the association of a corresponding random mouse signature
with the human HD signature (Table 1, column ‘P-value
rand. genes’). For each model, we thus generated random
mouse signatures by drawing (without replacement) groups
of N non-redundant mouse probe sets (i.e. N probe sets anno-
tated with N different genes) with at least one orthologous
probe set in humans. In the case of multiple orthologous
probe sets, we included the probe sets showing the most sig-
nificant differential expression. For each model, we then
obtained the concordance coefficient c for each of 1000
random mouse signatures and used this permutation distri-
bution to carry out the test [see Goeman and Buhlmann (56)
for a discussion of these two sampling schemes]. Small
changes in N (100–1000) did not qualitatively alter the
results obtained; data presented in Table 1 and Figures 2
and 3 are for N ¼ 200.
Comparison of gene expression changes in different
HD models
To investigate whether subsets of the HD models shared
similar patterns of gene expression changes and, in particular,
to ask whether they might recapitulate human HD in different
ways, we performed hierarchial clustering. To reduce techni-
cal heterogeneity, we limited this analysis to data sets col-
lected on Affymetrix Mouse 430 GeneChips (i.e. R6/2 6w,
R6/2 12w, CHL2Q150/Q150 22m, HdhQ92/Q92 3m, HdhQ92/Q92
18m, YAC128 12m and YAC128 24m) and to probe sets
present on both 430A and 430 2.0 formats (i.e. all probe
sets on 430A arrays). Where multiple mouse probe sets repre-
senting a single gene were identified, we selected the mouse
probe set reporting the largest absolute fold-change across
HD models (i.e. we selected the probe set with the largest
sum of squared log2 fold changes in the seven data sets).
We then selected the top 200 differentially expressed genes
from different data sets and used the corresponding log2 fold
changes in each model to calculate the pairwise distances
between every pair of HD models (based on Pearson’s corre-
lation coefficient) and clustered them using Ward’s agglom-
eration method (57). We first investigated whether the seven
models might recapitulate human HD in different ways by
clustering based on the top 200 human mRNA changes. In
addition, we explored whether mouse models expressing the
full-length mutant htt would show different changes in gene
expression than those expressing N-terminal htt fragments
by clustering using the top 500 probe sets for either the 22m
CHL2Q150/Q150 data set or 12 w R6/2 data set, representing
prototypical full-length and N-terminal fragment models,
respectively.
1858 Human Molecular Genetics, 2007, Vol. 16, No. 15
In order to define uniform HD-related gene expression
changes seen in multiple lines of mice, and to compare such
coordinate mouse regulations with those of human HD, we
implemented a meta-analysis strategy. We built two lists of
genes with same-sign regulations over four ‘early-stage’
models (R6/1, R6/2 6 weeks, CHL 2, HdhQ92/Q92 18 months,
hybridized on array format MG-U74Av2, 430 2.0,
MG-U74Av2, 430 2.0, respectively) and, separately, over
two ‘late-stage’ models (R6/2 12 weeks and CHL2Q150/Q150
22 months, both hybridized on array 430 2.0). For the
former list, we used gene IDs annotation provided by Affyme-
trix (07/27/2006) to map probe sets across the different array
formats. If multiple probe sets were annotated with a single
gene ID, we kept the probe set showing the most significant
expression change. We then selected genes targeted by a
probe set on all arrays and ordered them according to their
average rank over the individual lists of differentially
expressed genes (ordered by decreasing absolute mod
t-statistic). Genes with the lowest average ranks (i.e. consist-
ently differentially expressed in all of the HD models)
showed largely concordant regulations in the various HD
models. Finally, we mapped genes with concordant regu-
lations over the HD models to their human orthologs and com-
pared them with the (human orthologous) regulations found in
HD patients.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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